Biotechnology

(NPSP) The Secret to Picking Biotech Stocks

Yesterday, I was on Komodo Island, Indonesia, as part of The Oxford Club’s Chairman’s Circle cruise to Australia and Indonesia.

We saw the famed Komodo dragons, which are some of the most lethal animals in the world. When they bite, they release bacteria that stop the blood-clotting process,...

15Mar2014 | | Comments Off on (NPSP) The Secret to Picking Biotech Stocks | Continued

(PPHM) Peregrine Pharmaceuticals Shows Encouraging News

Peregrine Pharmaceuticals (PPHM) recently received encouraging news when the company announced that the US Food and Drug Administration (FDA) has agreed on the design for the phase III registration trial for its oncology candidate,...

26Sep2013 | | Comments Off on (PPHM) Peregrine Pharmaceuticals Shows Encouraging News | Continued

(NPSP) NPS Pharmaceuticals Prices Offering

NPS Pharmaceuticals, Inc. (NPSP) recently priced a public offering of 6,000,000 shares at $14.53 a share, with a 30-day over-allotment option for an additional 900,000 shares. NPS Pharma expects to raise approximately $87.2 million...

12Sep2013 | | Comments Off on (NPSP) NPS Pharmaceuticals Prices Offering | Continued

(ONCY) Oncolytics Biotech Sees Promising Data on Reolysin

Recently, Oncolytics Biotech Inc. (ONCY) reported positive preliminary results from the US phase II trial (REO 020) evaluating the use of oncology candidate, Reolysin in combination with Bristol-Myers Squibb‘s...

1Sep2013 | | Comments Off on (ONCY) Oncolytics Biotech Sees Promising Data on Reolysin | Continued

(XNPT) XenoPort Candidate Disappoints

XenoPort, Inc. (XNPT) recently reported disappointing results on arbaclofen placarbil (AP) from a pivotal late-stage study (n=228).

Results from the phase III trial showed that AP failed to achieve statistically significant...

7Aug2013 | | Comments Off on (XNPT) XenoPort Candidate Disappoints | Continued

(GILD) Gilead’s Sofosbuvir under European Review

Gilead Sciences Inc. (GILD) recently announced that its Marketing Authorisation Application (MAA) for HCV candidate sofosbuvir (formerly GS-7977), submitted to the European Medicines Agency (EMA) on Apr 17, 2013, has been validated...

4Aug2013 | | Comments Off on (GILD) Gilead’s Sofosbuvir under European Review | Continued

(XNPT) XenoPort Resumes Horizant Supply

XenoPort Inc. (XNPT) recently commenced shipments of Horizant extended-release tablets in the US. The drug is approved in the US for the treatment of moderate-to-severe primary restless legs syndrome (RLS) as well as for the management...

4Aug2013 | | Comments Off on (XNPT) XenoPort Resumes Horizant Supply | Continued

(RPRX) Repros to Therapeutics Conduct Phase IIb Trial

Recently, the US Food and Drug Administration (FDA) recommended Repros Therapeutics Inc. (RPRX) to conduct a phase IIb trial on its pipeline candidate, Proellex-V before commencing phase III studies.

The primary indication...

29Jul2013 | | Comments Off on (RPRX) Repros to Therapeutics Conduct Phase IIb Trial | Continued

(ACOR) Acorda Therapeutics Earns Additional Patent for Ampyra

Acorda Therapeutics, Inc. (ACOR) recently announced that an additional method of use patent (US patent application no. 8,440,703) related to Ampyra twice-daily dosing of less than 15 mg has been issued by the US Patent and Trademark...

26Jul2013 | | Comments Off on (ACOR) Acorda Therapeutics Earns Additional Patent for Ampyra | Continued

(SGEN) Seattle Genetics’ Adcetris under FDA Review

Seattle Genetics, Inc. (SGEN) recently announced that the US Food and Drug Administration (FDA) has accepted its supplemental biologics license application (sBLA) seeking approval of Adcetris (brentuximab vedotin) for an additional...

28Jun2013 | | Comments Off on (SGEN) Seattle Genetics’ Adcetris under FDA Review | Continued

(GILD) Gilead Sciences Shows Pipeline Progress

Gilead Sciences, Inc. (GILD) recently presented encouraging data on its pipeline candidate idelalisib (formerly GS-1101) from a phase II study (study 101-08: n=64). The study is evaluating idelalisib combined with Roche Holding...

4Jun2013 | | Comments Off on (GILD) Gilead Sciences Shows Pipeline Progress | Continued

(OPTR) Optimer Pharmaceuticals’ Dificid Cleared Down Under

Optimer Pharmaceuticals (OPTR) received encouraging news recently when the Australian regulatory body (Australian Therapeutic Goods Administration) cleared its drug Dificid (fidaxomicin). Dificid tablets were cleared for the treatment...

16May2013 | | Comments Off on (OPTR) Optimer Pharmaceuticals’ Dificid Cleared Down Under | Continued

(ARIA) Ariad Pharmaceuticals Posts Wider Year Over Year Loss

Ariad Pharmaceuticals, Inc. (ARIA) reported first quarter loss of 36 cents per share, wider than the year-ago loss of 25 cents per share but narrower than the Zacks Consensus Estimate of a loss of 37 cents per share.

First...

15May2013 | | Comments Off on (ARIA) Ariad Pharmaceuticals Posts Wider Year Over Year Loss | Continued

(LIFE) MedTech Industry Stock Update – May 2013 – Zacks Analyst Interviews

As expected, MedTech mergers and acquisitions (M&A) are heating up in 2013. Finally, the much-hyped takeover battle for Life Technologies Corporation (LIFE) came to an end last month with Thermo Fisher Scientific...

15May2013 | | Comments Off on (LIFE) MedTech Industry Stock Update – May 2013 – Zacks Analyst Interviews | Continued

(GILD) Gilead Sciences Suffers Double Setbacks

Gilead Sciences, Inc (GILD) suffered two successive setbacks when the US Food and Drug Administration (FDA) issued complete response letters (CRLs) to the company’s HIV candidates, elvitegravir and cobicistat, for use as part of...

1May2013 | | Comments Off on (GILD) Gilead Sciences Suffers Double Setbacks | Continued

(VPHM) ViroPharma Drug Candidate Pipeline Progresses

ViroPharma Incorporated (VPHM) recently announced results from a phase II study of its candidate VP20621 (non-toxigenic Clostridium difficile), which is being developed to prevent recurrent C. difficile infections (CDI), a gastrointestinal...

27Apr2013 | | Comments Off on (VPHM) ViroPharma Drug Candidate Pipeline Progresses | Continued

(IMGN) ImmunoGen to Focus on Pipeline

ImmunoGen Inc.(IMGN) recently provided an update on its pipeline and maintained its outlook for fiscal year 2013 (ending June 30) at its recently held Analyst & Investor Day.

ImmunoGen stated that its primary focus will...

27Apr2013 | | Comments Off on (IMGN) ImmunoGen to Focus on Pipeline | Continued

(LIFE) Thermo Fisher Scientific Wins Life Technologies Corporation Takeover Battle

Finally, the much hyped takeover battle for Life Technologies Corporation (LIFE) came to an end on Monday with Thermo Fisher Scientific (TMO) emerging as the clear...

27Apr2013 | | Comments Off on (LIFE) Thermo Fisher Scientific Wins Life Technologies Corporation Takeover Battle | Continued

(ACHN) Achillion Pharmaceuticals’ HCV Candidates Progress

Achillion Pharmaceuticals, Inc. (ACHN) recently commenced international phase II studies on sovaprevir and ACH-3102 for the treatment of genotype 1 chronic hepatitis C (HCV). The trial will assess an all-oral 12-week interferon-free...

21Apr2013 | | Comments Off on (ACHN) Achillion Pharmaceuticals’ HCV Candidates Progress | Continued

(ARIA) Ariad Pharmaceuticals Presents Data on AP26113

Ariad Pharmaceuticals, Inc. (ARIA) recently presented pre-clinical data on AP26113. The data presented by the company revealed that AP26113 can inhibit clinically relevant anaplastic lymphoba kinase (ALK) mutants resistant to Pfizer...

21Apr2013 | | Comments Off on (ARIA) Ariad Pharmaceuticals Presents Data on AP26113 | Continued

(RPRX) Repros Therapeutics Gets Additional Patents

Repros Therapeutics Inc. (RPRX) recently announced that two additional patents covering its candidate, Androxal, have been issued. Both patents (8,372,887 and 8,377,991) related to metabolic consequences of low testosterone and the...

21Apr2013 | | Comments Off on (RPRX) Repros Therapeutics Gets Additional Patents | Continued

(REGN) Regeneron Pharmaceuticals Rated Neutral Again

We recently maintained our Neutral recommendation on biopharmaceutical company, Regeneron Pharmaceuticals (REGN). Our target price is $195.00 per share.

Why the Reiteration?

Regeneron reported higher-than-expected...

18Apr2013 | | Comments Off on (REGN) Regeneron Pharmaceuticals Rated Neutral Again | Continued

(BSTC) BioSpecifics Technologies Annouces Positive Data on Xiaflex

BioSpecifics Technologies (BSTC) recently announced positive top line data from a phase IIa study on Xiaflex for the potential treatment of frozen shoulder syndrome (FSS) in adults. BioSpecifics has a strategic partnership with Auxilium...

18Apr2013 | | Comments Off on (BSTC) BioSpecifics Technologies Annouces Positive Data on Xiaflex | Continued

(GILD) Gilead Sciences Seeks FDA Approval

Gilead Sciences (GILD) recently submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval to market its hepatitis C Virus (HCV) candidate sofosbuvir (formerly GS-7977).

Gilead is looking...

18Apr2013 | | Comments Off on (GILD) Gilead Sciences Seeks FDA Approval | Continued

(BIIB) Biogen’s Tecfidera Approved by U.S. Food and Drug Administration

Tecfidera, Biogen Idec’s (BIIB) oral multiple sclerosis treatment, gained FDA approval recently for the first-line treatment of people with relapsing forms of multiple sclerosis. Biogen intends to launch the drug shortly.

Results...

30Mar2013 | | Comments Off on (BIIB) Biogen’s Tecfidera Approved by U.S. Food and Drug Administration | Continued

(THRX) Theravance Inks Deal for Vibativ

Theravance Inc. (THRX) recently entered into an agreement with UK-based Clinigen Group plc for the commercialization of Vibativ (telavancin) in the EU and several other European countries including Switzerland and Norway.

As...

24Mar2013 | | Comments Off on (THRX) Theravance Inks Deal for Vibativ | Continued

(AFFY) Affymax to Cut 75% of Workforce

Affymax, Inc. (AFFY) recently announced that it will reduce its total workforce by approximately 75% (230 employees). The company took this decision after it recalled all lots of Omontys (peginesatide) voluntarily along with its partner...

23Mar2013 | | Comments Off on (AFFY) Affymax to Cut 75% of Workforce | Continued

(CELG) Celgene Plans $600M Share Buyback

Celgene Corporation (CELG) recently entered into an accelerated share repurchase (ASR) agreement with an investment bank. The agreement will allow Celgene to repurchase around $600 million of its common stock. The move will boost...

2Mar2013 | | Comments Off on (CELG) Celgene Plans $600M Share Buyback | Continued

(CHTP) Chelsea Therapeutics International Shows Encouraging News

Chelsea Therapeutics International Ltd. (CHTP) recently announced that it received written guidance from the Director of the Office of New Drugs at the US Food and Drug Administration (FDA) regarding the resubmission of the New Drug...

1Mar2013 | | Comments Off on (CHTP) Chelsea Therapeutics International Shows Encouraging News | Continued

(SGEN) Seattle Genetics Starts SGN-CD19A Phase I Study

Seattle Genetics Inc. (SGEN) recently commenced two phase I clinical studies with its oncology candidate, SGN-CD19A. The two trials will assess the safety and anti-tumor response of SGN-CD19A in CD19-positive acute lymphoblastic leukemia...

27Feb2013 | | Comments Off on (SGEN) Seattle Genetics Starts SGN-CD19A Phase I Study | Continued